['colorectal cancer']
['fruquintinib', 'placebo']

        Inclusion Criteria:

          -  ≥ 18 and ≤ 75 years of age , with ≥ 40Kg

          -  Histological or cytological confirmed colorectal cancer

          -  ECOG performance status of 0-1

          -  Standard regimen failed or no standard regimen available

          -  Adequate hepatic, renal, heart, and hematologic functions

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

          -  Signed and dated informed consent

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedure

        Exclusion Criteria:

          -  - Pregnant or lactating women

          -  Any factors that influence the usage of oral administration

          -  Evidence of CNS metastasis

          -  Intercurrence with one of the following: non-controlled hypertension, coronary artery
             disease, arrhythmia and heart failure

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR
             inhibition

          -  Disability of serious uncontrolled intercurrence infection

          -  Proteinuria ≥ 2+ (1.0g/24hr)

          -  Have evidence or a history of bleeding tendency within two months of the enrollment,
             regardless of seriousness

          -  Within 12 months before the first treatment occurs artery/venous thromboembolic
             events, such as cerebral vascular accident (including transient ischemic attack) etc.

          -  Within 6 months before the first treatment occurs acute myocardial infarction, acute
             coronary syndrome or CABG

          -  Bone fracture or wounds that was not cured for a long time

          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy
      